Side-by-side · Research reference

HCGvsIGF-DES

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedHUMAN-REVIEWED12/52 cited

BAnimal-StrongHUMAN-REVIEWED8/60 cited

HCG

Glycoprotein Hormone · LH Mimetic

2,000 IUTypical dose (2×/wk)Konsam 2026 Zachariou 2026

70–90%Sperm induction rateHuijben 2026 Zachariou 2026

12–24 moTime to sperm appearanceHuijben 2026 Nariyoshi 2025

IM or SQ · 2–3×/week

IGF-DES

IGF-1 Analogue · Truncated N-Terminal

~10×Potency vs IGF-1

ReducedIGFBP binding

ResearchStatus

Injection (local or systemic) · Research protocols onlyBredehöft 2008

01Mechanism of Action

Parameter

HCG

IGF-DES

Primary target

LH receptors on testicular Leydig cellsSchröder-Lange 2025

IGF-1 receptor (IGF1R)Shields 2007

Pathway

hCG → Leydig cell LH receptor → Intracellular cAMP → Steroidogenesis pathway activation → Testosterone synthesis

IGF1R activation → PI3K/Akt & MAPK signaling → protein synthesis, proliferation

Downstream effect

Elevated intratesticular testosterone, restored spermatogenesis, virilization, secondary sex characteristic developmentKonsam 2026 Zachariou 2026

Enhanced muscle protein synthesis, myoblast differentiation, reduced apoptosis, cell proliferation

Feedback intact?

No — exogenous hCG bypasses hypothalamic-pituitary axis; endogenous LH remains suppressed

Unknown — no human endocrine feedback data

Origin

Heterodimeric glycoprotein (alpha subunit shared with LH/FSH/TSH; beta subunit confers specificity). Available as urinary-derived or recombinant formulations.

Synthetic truncation of native IGF-1 — removal of N-terminal Gly-Pro-Glu tripeptideBredehöft 2008

Antibody development

Rare with recombinant; possible with urinary-derived formulations

—

02Dosage Protocols

Parameter

HCG

IGF-DES

Hypogonadotropic hypogonadism (monotherapy)

2,000 IU IM/SQ 2–3×/weekKonsam 2026 Zachariou 2026

Titrate to normalize testosterone (300–1,000 ng/dL) or achieve target AMH ~7.4 ng/mL.

—

Combined therapy (hCG + FSH)

hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wkKonsam 2026 Nariyoshi 2025

Preferred for azoospermia; FSH added after initial hCG phase or from outset.

—

Triple therapy (experimental)

hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wk + testosterone 100 mg IM q2wkKonsam 2026

May accelerate virilization; reduces hCG requirements (~30% lower cumulative dose vs monotherapy).

—

Cryptorchidism (pediatric)

500–4,000 IU IM 2–3×/week for 3–6 weeks

—

Evidence basis

RCT / Meta-analysis / FDA-approvedKonsam 2026 Huijben 2026

Animal models + in vitro only

Duration to sperm appearance

12–24 months (median ~18 mo)Huijben 2026 Zachariou 2026

Congenital HH may require longer treatment; acquired HH responds faster.

—

Route

Intramuscular or subcutaneousKonsam 2026

Subcutaneous or intramuscular (local injection favored)

Local delivery maximizes tissue-specific uptake.

Monitoring

Serum testosterone, semen analysis q3–6mo, testicular ultrasound

Thickened seminiferous tubules (>300 μm) on ultrasound predict imminent sperm appearance.Nariyoshi 2025

—

Research dose range

—

10–100 ng/mL (in vitro); μg doses (animal models)

Highly context-dependent; no standardized human protocol.

Frequency

—

Variable — daily to multiple times daily in research

Human data

—

None — no clinical trials

Half-life

—

Shorter than IGF-1 due to reduced IGFBP binding

Rapid tissue uptake, limited systemic circulation.

03Metabolic / Fat Loss Evidence

Parameter

HCG

IGF-DES

Primary mechanism

—

Indirect via muscle hypertrophy → metabolic rate elevation

Direct lipolysis

—

Minimal evidence — IGF-1 axis primarily anabolic, not lipolytic

Prostate model

—

Inhibited BPH cell proliferation when combined with vitamin D3 analogueCrescioli 2002

Context-specific anti-proliferative effect, not fat loss.

04Side Effects & Safety

Parameter

HCG

IGF-DES

Injection site reaction

Pain, erythema (mild, transient)

Expected — erythema, irritation, local swelling

Gynecomastia

Aromatization of elevated testosterone to estradiol; dose-dependent

—

Testicular discomfort / Edema

Rapid testicular growth in hypogonadal males; usually self-limiting

—

Polycythemia

Elevated hematocrit from supraphysiological testosterone; monitor CBC

—

Mood / Libido changes

Variable; usually positive with normalization of testosterone

—

Acne / Oily skin

Androgen-mediated; dose-dependent

—

Prostate concerns

Monitor PSA in older males; hCG restores physiological testosterone (not supraphysiological)

—

Antibody formation

Rare with recombinant; possible with urinary-derived

—

Hypoglycemia risk

—

Theoretical — IGF-1 axis enhances glucose uptake

Mitogenic risk

—

Chronic IGF-1 receptor activation may promote cell proliferation, potential tumor growthCrescioli 2002

Edema / Fluid retention

—

Possible via sodium retention (IGF-1 axis effect)

Human safety data

—

Absent — no human trials, all effects theoretical or extrapolated

Unknown long-term effects

—

No chronic dosing studies in humans; endocrine, metabolic consequences unknown

Absolute Contraindications

HCG

·Androgen-dependent malignancy (prostate, breast cancer)
·Hypersensitivity to hCG or excipients
·Precocious puberty

IGF-DES

·Active malignancy or history of cancer (mitogenic risk)
·Pregnancy / lactation (no safety data)
·Hypoglycemia disorders

Relative Contraindications

HCG

·Untreated obstructive sleep apnea
·Severe cardiovascular disease (polycythemia risk)
·History of thromboembolism

IGF-DES

·Diabetes mellitus (unpredictable glucose effects)
·Renal or hepatic impairment (clearance unknown)
·Edema-prone conditions (heart failure, nephrotic syndrome)

05Administration Protocol

Parameter

HCG

IGF-DES

1. Reconstitution (if lyophilized)

Add sterile water or bacteriostatic water per manufacturer instructions. Typically 1–2 mL per 5,000–10,000 IU vial. Roll gently — do not shake. Solution should be clear.

Des(1-3)IGF-1 has no approved human protocol. All administration details are derived from animal or in vitro research and should not be construed as medical guidance.

2. Injection site

Intramuscular: ventrogluteal, vastus lateralis, or deltoid. Subcutaneous: abdomen, avoiding navel (2-inch radius). Rotate sites to prevent lipohypertrophy.

Sterile water or bacteriostatic water per research protocol. Gently swirl; do not shake. Store reconstituted peptide at 2–8 °C.

3. Timing

Administer 2–3 times per week. Consistent weekly schedule recommended (e.g., Monday/Thursday or Monday/Wednesday/Friday).

Subcutaneous (abdomen, thigh) or intramuscular (deltoid, vastus lateralis). Local injection to target tissue (e.g., muscle group) may enhance regional uptake.

4. Storage

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C. Bacteriostatic water extends shelf life to ~30 days; sterile water use within 72 hours.

Frequency and timing vary by research design. Post-exercise or fasted state may theoretically enhance muscle uptake.

5. Needle selection

IM: 21–23G, 1–1.5 inch. SQ: 25–27G, 5/8 inch. Inject slowly (30–60 seconds for IM).

27–31G insulin syringe for subcutaneous; 25–27G for intramuscular.

6. Monitoring

—

Glucose monitoring essential (hypoglycemia risk). No established IGF-1 or safety labs for human use.

06Stack Synergy

HCG

— no documented stacks

IGF-DES

+ BPC-157

Moderate

View BPC-157 →

Des(1-3)IGF-1 promotes myoblast differentiation and protein synthesis, while BPC-157 enhances tissue repair, angiogenesis, and collagen synthesis. Both act on distinct pathways (IGF1R vs gastric pentadecapeptide mechanisms) to support muscle recovery and connective tissue integrity. Synergy is mechanistic but lacks direct co-administration studies.

Des(1-3)IGF-1: Research dose post-workout (local IM)
BPC-157: 250–500 mcg SQ, daily or twice daily
Frequency: Daily or per research protocol
Primary benefit: Accelerated muscle repair, enhanced hypertrophy, connective tissue support

+ TB-500

Moderate

View TB-500 →

TB-500 (Thymosin Beta-4 fragment) promotes cell migration, angiogenesis, and wound healing via actin regulation. Des(1-3)IGF-1 drives protein synthesis and myoblast proliferation. Combined, these peptides may synergistically enhance muscle recovery, repair, and hypertrophy through complementary anabolic and regenerative pathways. No direct human co-administration data.

Des(1-3)IGF-1: Research dose post-workout (local IM)
TB-500: 2–5 mg SQ, 2× weekly
Frequency: Per research cycle
Primary benefit: Muscle hypertrophy, injury recovery, vascular support